This HTML5 document contains 132 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n10http://linked.opendata.cz/resource/drugbank/drug/DB00222/identifier/pubchem-compound/
n26http://linked.opendata.cz/resource/AHFS/
n11http://linked.opendata.cz/resource/drugbank/drug/DB00222/identifier/pubchem-substance/
foafhttp://xmlns.com/foaf/0.1/
n29http://linked.opendata.cz/resource/mesh/concept/
n8http://linked.opendata.cz/resource/drugbank/company/
n30http://linked.opendata.cz/resource/drugbank/dosage/
n15http://linked.opendata.cz/resource/drugbank/drug/DB00222/identifier/kegg-drug/
n19http://linked.opendata.cz/resource/drugbank/mixture/
n16http://linked.opendata.cz/resource/drugbank/drug/DB00222/identifier/drugbank/
n12http://linked.opendata.cz/resource/drugbank/drug/DB00222/identifier/national-drug-code-directory/
n23http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n18http://www.rxlist.com/cgi/generic/
n7http://linked.opendata.cz/resource/drugbank/drug/DB00222/identifier/chemspider/
n24http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n9http://linked.opendata.cz/resource/drugbank/medicinal-product/
n6http://linked.opendata.cz/resource/drugbank/drug/DB00222/identifier/chebi/
owlhttp://www.w3.org/2002/07/owl#
n28http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n31http://www.drugs.com/cdi/
n4http://linked.opendata.cz/resource/drugbank/property/
n21http://linked.opendata.cz/resource/drugbank/drug/DB00222/identifier/wikipedia/
xsdhhttp://www.w3.org/2001/XMLSchema#
n13http://linked.opendata.cz/resource/drugbank/drug/DB00222/identifier/pharmgkb/
n14http://linked.opendata.cz/resource/drugbank/drug/DB00222/identifier/kegg-compound/
n27http://linked.opendata.cz/resource/atc/
n25http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00222
rdf:type
n3:Drug
n3:description
Glimepiride is the first III generation sulphonyl urea it is a very potent sulphonyl urea with long duration of action.
n3:dosage
n30:271B5F93-363D-11E5-9242-09173F13E4C5 n30:271B5F94-363D-11E5-9242-09173F13E4C5 n30:271B5F95-363D-11E5-9242-09173F13E4C5 n30:271B5F96-363D-11E5-9242-09173F13E4C5 n30:271B5F97-363D-11E5-9242-09173F13E4C5 n30:271B5F98-363D-11E5-9242-09173F13E4C5
n3:group
approved
n3:halfLife
Approximately 5 hours following single dose.
n3:indication
For concomitant use with insulin for the treatment of noninsulin-dependent (type 2) diabetes mellitus.
n3:manufacturer
n8:271B5F83-363D-11E5-9242-09173F13E4C5 n8:271B5F84-363D-11E5-9242-09173F13E4C5 n8:271B5F81-363D-11E5-9242-09173F13E4C5 n8:271B5F82-363D-11E5-9242-09173F13E4C5 n8:271B5F80-363D-11E5-9242-09173F13E4C5 n8:271B5F8B-363D-11E5-9242-09173F13E4C5 n8:271B5F8C-363D-11E5-9242-09173F13E4C5 n8:271B5F89-363D-11E5-9242-09173F13E4C5 n8:271B5F8A-363D-11E5-9242-09173F13E4C5 n8:271B5F87-363D-11E5-9242-09173F13E4C5 n8:271B5F88-363D-11E5-9242-09173F13E4C5 n8:271B5F85-363D-11E5-9242-09173F13E4C5 n8:271B5F86-363D-11E5-9242-09173F13E4C5
owl:sameAs
n23:DB00222 n24:DB00222
dcterms:title
Glimepiride
adms:identifier
n6:5383 n7:3357 n10:3476 n11:46508842 n12:61442-115-01 n13:PA449761 n14:C07669 n15:D00593 n16:DB00222 n21:Glimepiride
n3:mechanismOfAction
The mechanism of action of glimepiride in lowering blood glucose appears to be dependent on stimulating the release of insulin from functioning pancreatic beta cells, and increasing sensitivity of peripheral tissues to insulin. Glimepiride likely binds to ATP-sensitive potassium channel receptors on the pancreatic cell surface, reducing potassium conductance and causing depolarization of the membrane. Membrane depolarization stimulates calcium ion influx through voltage-sensitive calcium channels. This increase in intracellular calcium ion concentration induces the secretion of insulin.
n3:packager
n8:271B5F6F-363D-11E5-9242-09173F13E4C5 n8:271B5F70-363D-11E5-9242-09173F13E4C5 n8:271B5F6D-363D-11E5-9242-09173F13E4C5 n8:271B5F6E-363D-11E5-9242-09173F13E4C5 n8:271B5F73-363D-11E5-9242-09173F13E4C5 n8:271B5F74-363D-11E5-9242-09173F13E4C5 n8:271B5F71-363D-11E5-9242-09173F13E4C5 n8:271B5F72-363D-11E5-9242-09173F13E4C5 n8:271B5F67-363D-11E5-9242-09173F13E4C5 n8:271B5F68-363D-11E5-9242-09173F13E4C5 n8:271B5F65-363D-11E5-9242-09173F13E4C5 n8:271B5F66-363D-11E5-9242-09173F13E4C5 n8:271B5F6B-363D-11E5-9242-09173F13E4C5 n8:271B5F6C-363D-11E5-9242-09173F13E4C5 n8:271B5F69-363D-11E5-9242-09173F13E4C5 n8:271B5F6A-363D-11E5-9242-09173F13E4C5 n8:271B5F5F-363D-11E5-9242-09173F13E4C5 n8:271B5F60-363D-11E5-9242-09173F13E4C5 n8:271B5F5D-363D-11E5-9242-09173F13E4C5 n8:271B5F5E-363D-11E5-9242-09173F13E4C5 n8:271B5F63-363D-11E5-9242-09173F13E4C5 n8:271B5F64-363D-11E5-9242-09173F13E4C5 n8:271B5F61-363D-11E5-9242-09173F13E4C5 n8:271B5F62-363D-11E5-9242-09173F13E4C5 n8:271B5F5B-363D-11E5-9242-09173F13E4C5 n8:271B5F5C-363D-11E5-9242-09173F13E4C5 n8:271B5F7F-363D-11E5-9242-09173F13E4C5 n8:271B5F7D-363D-11E5-9242-09173F13E4C5 n8:271B5F7E-363D-11E5-9242-09173F13E4C5 n8:271B5F77-363D-11E5-9242-09173F13E4C5 n8:271B5F78-363D-11E5-9242-09173F13E4C5 n8:271B5F75-363D-11E5-9242-09173F13E4C5 n8:271B5F76-363D-11E5-9242-09173F13E4C5 n8:271B5F7B-363D-11E5-9242-09173F13E4C5 n8:271B5F7C-363D-11E5-9242-09173F13E4C5 n8:271B5F79-363D-11E5-9242-09173F13E4C5 n8:271B5F7A-363D-11E5-9242-09173F13E4C5
n3:synonym
Glimépiride Glimepiridum Amaryl Glimepirida
n3:toxicity
Severe hypoglycemic reactions with coma, seizure, or other neurological impairment.
n3:volumeOfDistribution
* 21.8 ± 13.9 L [Volunteers] * 19.8 ± 12.7 L [Patients with Type 2 diabetes, Single Dose] * 37.1 ± 18.2 L [Patients with Type 2 diabetes, Multiple Dose]
n25:hasAHFSCode
n26:68-20-20
n3:foodInteraction
Even though food reduces product absorption, the manufacturer recommends taking the product with the first meal of the day. Avoid alcohol.
n3:mixture
n19:271B5F59-363D-11E5-9242-09173F13E4C5 n19:271B5F5A-363D-11E5-9242-09173F13E4C5
n3:proteinBinding
Over 99.5% bound to plasma protein.
n3:synthesisReference
Suresh Kadam, Venkatasubramanian Tarur, Sanjay Naik, Sachin Gavhane, "Process for preparation of substantially pure glimepiride." U.S. Patent US20070082943, issued April 12, 2007.
n28:hasConcept
n29:M0161111
foaf:page
n18:glimepiride.htm n31:glimepiride.html
n3:IUPAC-Name
n4:271B5F9D-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B5FA3-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B5FA2-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B5F9F-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B5FA0-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B5FA1-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B5FB3-363D-11E5-9242-09173F13E4C5 n4:271B5F9B-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B5FB5-363D-11E5-9242-09173F13E4C5 n4:271B5F99-363D-11E5-9242-09173F13E4C5 n4:271B5F9C-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B5F9A-363D-11E5-9242-09173F13E4C5
n25:hasATCCode
n27:A10BB12
n3:H-Bond-Acceptor-Count
n4:271B5FA9-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B5FAA-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B5FA4-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B5FA5-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B5FA7-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B5FA6-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B5FA8-363D-11E5-9242-09173F13E4C5
n3:absorption
Completely (100%) absorbed following oral administration.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
93479-97-1
n3:category
n3:clearance
* 52.1 +/- 16.0 mL/min [Normal subjects with single oral dose] * 48.5 +/- 29.3 mL/min [Patients with Type 2 diabetes, with single oral dose] * 52.7 +/- 40.3 mL/min [Patients with Type 2 diabetes, with multiple oral dose] * 47.8 mL/min [healthy after intravenous (IV) dosing]
n3:containedIn
n9:271B5F8E-363D-11E5-9242-09173F13E4C5 n9:271B5F8F-363D-11E5-9242-09173F13E4C5 n9:271B5F8D-363D-11E5-9242-09173F13E4C5 n9:271B5F92-363D-11E5-9242-09173F13E4C5 n9:271B5F90-363D-11E5-9242-09173F13E4C5 n9:271B5F91-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B5FAF-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B5FB1-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B5FB2-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B5FB4-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B5FAE-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B5FAD-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B5FB0-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B5F9E-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B5FAB-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B5FAC-363D-11E5-9242-09173F13E4C5